Steenholdt Casper, Ainsworth Mark, Thomsen Ole Østergaard, Brynskov Jørn, Bendtzen Klaus
Herlev Hospital, Institut for Inflammationsforskning, IIR7521, Rigshospitalet, DK-2100 København Ø, Denmark.
Ugeskr Laeger. 2010 Jan 4;172(1):44-7.
Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.
用抗肿瘤坏死因子-α（TNF）抗体治疗炎症性肠病（IBD）是有效的。然而，并非所有患者都有反应，而且随着时间的推移，相当一部分初始有反应者的疗效会逐渐消失。生物利用度、药代动力学和免疫原性的个体差异现在被认为是使用生物制剂的关键问题，采用可靠且与临床相关的方法对功能性抗TNF抗体和抗抗TNF药物抗体进行血液检测，可能通过个体化治疗方案优化IBD的治疗。
